Black Rock Inc. Aprea Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	SELL	$0.32 - $15.2 $118 - $5,624	-370 Reduced 0.2%	185,371 $61,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $736 - $14,116	-1,038 Reduced 0.56%	185,741 $121,000
Q2 2022 Aug 12, 2022	SELL	$0.62 - $1.94 $26,899 - $84,168	-43,386 Reduced 18.85%	186,779 $140,000
Q1 2022 May 12, 2022	SELL	$1.59 - $3.16 $3,253 - $6,465	-2,046 Reduced 0.88%	230,165 $428,000
Q4 2021 Feb 10, 2022	SELL	$2.87 - $5.58 $350,323 - $681,117	-122,064 Reduced 34.45%	232,211 $667,000
Q3 2021 Nov 09, 2021	SELL	$3.43 - $5.63 $11,442 - $18,781	-3,336 Reduced 0.93%	354,275 $1.81 Million
Q2 2021 Aug 11, 2021	BUY	$4.05 - $5.5 $1.45 Million - $1.97 Million	357,611 New	357,611 $1.74 Million

Others Institutions Holding APRE

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.